Handelsbanken Fonder AB Acquires Shares of 160,900 Oruka Therapeutics, Inc. $ORKA

Handelsbanken Fonder AB bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 160,900 shares of the company’s stock, valued at approximately $15,313,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its stake in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada raised its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at $1,295,854.56. This represents a 39.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 181,406 shares of company stock valued at $11,586,733. 23.49% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group raised their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Monday, August 3rd. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday. Finally, Wedbush reaffirmed an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $108.12 on Friday. Oruka Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $109.42. The stock has a market capitalization of $7.16 billion, a P/E ratio of -53.26 and a beta of -0.34. The stock has a fifty day moving average of $86.50 and a 200-day moving average of $62.27.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.